Objectives: To assess the oritavancin spectrum and activity against 2811 rarer species of coagulase-negative staphylococci (CoNS), streptococci and other Gram-positive species.
Introduction
Oritavancin is a bactericidal lipoglycopeptide for which two multicentre clinical trials (SOLO I and II) were completed in December 2012 and July 2013, respectively. 1 These trials assessed the efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), compared with vancomycin. 1 This drug has documented in vitro activity against frequently isolated Gram-positive pathogens during longitudinal surveillance studies. 2 Oritavancin MIC 50 and MIC 90 results of 0.03 and 0.06 mg/L, respectively, have been reported against MRSA. 3, 4 In addition, coagulase-negative staphylococci (CoNS; MIC 50/90 , 0.03/0.06 mg/L), Streptococcus pyogenes (MIC 50/90 , 0.12/ 0.25 mg/L), vancomycin-resistant (VanA) Enterococcus faecalis (MIC 50/90 , 0.25/0.5 mg/L) and Enterococcus faecium (MIC 50/90 , 0.03/0.12 mg/L) 4 and S. aureus and CoNS with elevated vancomycin MIC values (MIC 50/90 , 0.12/0.25 mg/L, for both) have demonstrated low oritavancin MIC results. 5 Gram-positive organisms (staphylococci, enterococci and streptococci) are commonly responsible for infections in nosocomial and community settings. More often than appreciated, these infections may involve a causative agent exhibiting a multidrug resistance phenotype and, when associated with critically ill patients, may provide an even greater challenge for antimicrobial therapies. 6 In addition, infections caused by Gram-positive pathogens less often recovered in clinical settings and for which in vitro data are limited, are scenarios experienced by health practitioners. Therefore, this study assessed the in vitro activity of oritavancin against rarely isolated CoNS, streptococci and other Gram-positive pathogens recovered from hospitalized patients during a 5 year longitudinal, multicentre, SENTRY Antimicrobial Surveillance Program for oritavancin.
Material and methods

Clinical isolates
A total of 2057 CoNS (14 species), 674 streptococci (7 groups) and 80 other Gram-positive species (3 genera) collected over a 5 year period as part of the SENTRY Program (2008-12) were included. Isolates were primarily identified by the participating laboratory and identification was confirmed by the reference monitoring laboratory (JMI Laboratories, North Liberty, IA, USA) by standard algorithms and Vitek w 2 (bioMérieux, Hazelwood, MO, USA) and supported by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany).
Antimicrobial susceptibility testing
Isolates were tested for susceptibility by broth microdilution following the CLSI M07-A9 document. 7 Testing was performed using panels manufactured by Thermo Fisher Scientific (Cleveland, OH, USA). These panels provide results equivalent to the CLSI-approved broth microdilution method supplemented with 0.002% polysorbate 80. 8 Quality assurance was performed by concurrent testing of CLSI-recommended (M100-S23, 2013) strains: E. faecalis ATCC 29212, S. aureus ATCC 29213 and Streptococcus pneumoniae ATCC 49619. 8 Results and discussion This study presents in vitro data for oritavancin tested against 2811 Gram-positive isolates that are rarely recovered from human clinical specimens and, as a consequence, limited susceptibility information is available in the public domain for these organism groups. Moreover, this report not only provides susceptibility data against several groups of streptococci and staphylococci, but also for numerous species within these groups of organisms, noting subtle differences in the susceptibility profiles within the investigated species. Oritavancin demonstrated potent activity against these species, inhibiting 99.4% of the tested isolates at ≤0.12 mg/L. In summary, the results presented herein enhance the oritavancin in vitro spectrum of activity prior to regulatory review by the FDA and European Medicines Agency, including against S. lugdunensis and the Streptococcus anginosus and S. dysgalactiae groups, which are pathogens responsible for the sought ABSSSI indication.
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